news
Oral contraceptive pills protect against ovarian and endometrial cancer, study finds
A study has shown that the use of oral contraceptives gave women a much lower risk of developing both ovarian and endometrial cancer.
List view / Grid view
Breast cancer
news
Intraoperative radiotherapy as effective as external beam radiotherapy, finds study
Researchers reveal that for early breast cancer a single dose of targeted intraoperative radiotherapy (TARGIT-IORT) is as effective at preventing breast cancer recurrence as the standard of care.
article
Top 10 biopharma workplaces in the US
A Fortune report reveals the best 10 places to work in the US biopharmaceutical industry.
news
FDA approves new administration route for Phesgo to treat breast cancer
The FDA has given approval to Phesgo for injection under the skin to treat HER2-positive breast cancer, meaning it can be administered at home by a healthcare professional.
news
EMA recommends updating safety information for HRT and leuprorelin
The EMA has suggested that the safety information be updated for HRT, to reflect a higher risk of breast cancer and recommends new measures for the handling of leuprorelin depot medicines.
news
Committee for Medicinal Products for Human Use (CHMP) meeting highlights
A summary of the CHMP meeting conclusions, including medicines recommended for approval and indication extension and several safety review findings.
news
Nanoparticle drug delivery could be the future of targeted cancer therapies
Researchers have created targeted, modifiable nanoparticles which could be combined with pharmaceuticals as a form of drug delivery to treat cancer.
article
Summarising 2019: a year of firsts for the EMA
The EMA was a proactive force in 2019, granting marketing authorisation for a range of drugs. This article highlights some of the most important advancements made by the agency last year.
news
NICE approves palbociclib with fulvestrant on the CDF for treatment of some breast cancers
The NICE committee has made palbociclib with fulvestrant available on the Cancer Drug Fund for patients with hormone receptor-positive, HER2-negative, advanced breast cancer.
news
WHO announces first biosimilar medicine pre-qualification
A trastuzumab biosimilar has been pre-qualified by WHO, marking its first, to improve access to the breast cancer treatment.
news
More effective, safe drugs drive biobetter market growth
The global biobetters market is set to increase due to demand for higher efficacy and safer drugs.
news
Proposed biosimilar accepted for review by EMA
The EMA has accepted Prestige BioPharma’s marketing application for its trastuzumab biosimilar.
news
‘Smart drug’ shows promise for metastatic triple-negative breast cancer
A study has shown that a 'smart drug' that delivers a toxic payload directly to tumour cells could be a possible treatment for breast cancer...
news
Oxybutynin improves quality of life for breast cancer survivors
Oxybutynin could help breast cancer survivors who are affected by increased hot flushes through cancer treatment, improving their quality of life...
news
Phase III KATHERINE trial crossed early reporting boundary and met its primary endpoint
A phase III clinical trial showed that neoadjuvant chemotherapy and trastuzumab reduced the risk of recurrence of HER2-positive early-stage breast cancer...
